VIFOR WEBSITE FIRST PAGE EXCUSEme IF YOU KNOW THIS ALREADY
May 23, 2017 18:53:15 GMT
opkfrostfan likes this
Post by Deleted on May 23, 2017 18:53:15 GMT
We extended our product portfolio in this area by acquiring exclusive rights to OPKO’s new investigative drug for the treatment of secondary hyperparathyroidism (SHPT) in patients with CKD and vitamin D insufficiency (CTAP101 Capsules).Vifor Pharma – link to home page
About Vifor Pharma Group
Products
R&D
Investors
Media
Career
VFMCRP
EN DE FR
HOMEABOUT VIFOR PHARMA GROUPVFMCRP
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA
PARTNER OF CHOICE FOR RENAL PHARMACEUTICALS AND INNOVATIVE, PATIENT-FOCUSED SOLUTIONS
Vifor Fresenius Medical Care Renal Pharma is a rapidly-growing international company that focuses on nephrology. We combine the strengths of our two shareholders: Vifor Pharma, a pharmaceutical company specialising in the treatment of iron deficiency, and Fresenius Medical Care, one of the world’s leading providers of expert patient care and dialysis services.
We develop and commercialise high quality, innovative products that help patients with chronic kidney disease (CKD) to manage their condition and to live better, healthier and more fulfilling lives. We work in partnership with specialist clinics, healthcare professionals, payors and patients to offer them the most comprehensive portfolio of nephrology products. These cover five essential therapeutic areas: anaemia management; mineral & bone disorders management; cardio-renal management; CKD progression; and
kidney transplantation.
The anaemia management portfolio includes the intravenous iron products Ferinject® and Venofer® for the treatment of iron deficiency and iron deficiency anaemia in pre-dialysis and dialysis. We also have an exclusive licensing agreement with Roche to commercialise Mircera®, a long-acting Erythropoietin Stimulating Agent (ESA) for the treatment of symptomatic anaemia associated with CKD, in the USA and Puerto Rico.
In mineral & bone disorders management, we offer the phosphate binders Velphoro®, newly developed and indicated for the treatment of hyperphosphatemia in CKD patients on dialysis, and Osvaren®. We extended our product portfolio in this area by acquiring exclusive rights to OPKO’s new investigative drug for the treatment of secondary hyperparathyroidism (SHPT) in patients with CKD and vitamin D insufficiency (CTAP101 Capsules).
Our cardio-renal management portfolio includes the rights to market Relypsa’s Patiromer FOS (US brand name: Veltassa®), a new potassium binder for patients with hyperkalemia, in markets outside the US and Japan. Patiromer FOS has been submitted for approval in Europe.
As these collaborations demonstrate, Vifor Fresenius Medical Care Renal Pharma is increasingly the partner of choice for innovative nephrology products. By combining pharmaceutical expertise and day-to-day understanding of the patient experience, Vifor Fresenius Medical Care Renal Pharma is continually seeking new ways to improve treatment options for clinicians and to drive better patient care, working to complement our unrivalled portfolio of nephrology medicines with new technologies and treatment modalities to provide truly integrated solutions.
LinkedInYoutube
About Vifor Pharma Group
Products
R&D
Investors
Media
Career
VFMCRP
EN DE FR
HOMEABOUT VIFOR PHARMA GROUPVFMCRP
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA
PARTNER OF CHOICE FOR RENAL PHARMACEUTICALS AND INNOVATIVE, PATIENT-FOCUSED SOLUTIONS
Vifor Fresenius Medical Care Renal Pharma is a rapidly-growing international company that focuses on nephrology. We combine the strengths of our two shareholders: Vifor Pharma, a pharmaceutical company specialising in the treatment of iron deficiency, and Fresenius Medical Care, one of the world’s leading providers of expert patient care and dialysis services.
We develop and commercialise high quality, innovative products that help patients with chronic kidney disease (CKD) to manage their condition and to live better, healthier and more fulfilling lives. We work in partnership with specialist clinics, healthcare professionals, payors and patients to offer them the most comprehensive portfolio of nephrology products. These cover five essential therapeutic areas: anaemia management; mineral & bone disorders management; cardio-renal management; CKD progression; and
kidney transplantation.
The anaemia management portfolio includes the intravenous iron products Ferinject® and Venofer® for the treatment of iron deficiency and iron deficiency anaemia in pre-dialysis and dialysis. We also have an exclusive licensing agreement with Roche to commercialise Mircera®, a long-acting Erythropoietin Stimulating Agent (ESA) for the treatment of symptomatic anaemia associated with CKD, in the USA and Puerto Rico.
In mineral & bone disorders management, we offer the phosphate binders Velphoro®, newly developed and indicated for the treatment of hyperphosphatemia in CKD patients on dialysis, and Osvaren®. We extended our product portfolio in this area by acquiring exclusive rights to OPKO’s new investigative drug for the treatment of secondary hyperparathyroidism (SHPT) in patients with CKD and vitamin D insufficiency (CTAP101 Capsules).
Our cardio-renal management portfolio includes the rights to market Relypsa’s Patiromer FOS (US brand name: Veltassa®), a new potassium binder for patients with hyperkalemia, in markets outside the US and Japan. Patiromer FOS has been submitted for approval in Europe.
As these collaborations demonstrate, Vifor Fresenius Medical Care Renal Pharma is increasingly the partner of choice for innovative nephrology products. By combining pharmaceutical expertise and day-to-day understanding of the patient experience, Vifor Fresenius Medical Care Renal Pharma is continually seeking new ways to improve treatment options for clinicians and to drive better patient care, working to complement our unrivalled portfolio of nephrology medicines with new technologies and treatment modalities to provide truly integrated solutions.
LinkedInYoutube